Literature DB >> 29801818

Cyclic nigerosyl-1,6-nigerose-based nanosponges: An innovative pH and time-controlled nanocarrier for improving cancer treatment.

F Caldera1, M Argenziano2, F Trotta1, C Dianzani2, L Gigliotti3, M Tannous1, L Pastero4, D Aquilano4, T Nishimoto5, T Higashiyama6, R Cavalli7.   

Abstract

The design and structural optimisation of a novel polysaccharide-based nanomaterial for the controlled and sustained release of doxorubicin are here reported. A cross-linked polymer was obtained by reacting a tetraglucose, named cyclic nigerosyl-1-6-nigerose (CNN), with pyromellitic dianhydride. The cross-linking reaction formed solid nanoparticles, named nanosponges, able to swell as a function of the pH. Nanoparticle sizes were reduced using High Pressure Homogenization, to obtain uniform nanosuspensions. Doxorubicin was incorporated into the CNN-nanosponges in a good extent. DSC and solid state NMR analyses proved the drug interaction with the polymer matrix. In vitro studies demonstrated pH-dependent slow and prolonged release kinetics of the drug from the nanoformulation. Doxorubicin-loaded CNN-nanosponges were easily internalized in A2780 cell line. They might considered an intracellular doxorubicin reservoir, able to slowly release the drug over time. CNN-nanosponges may be promising biocompatible nanocarriers for the sustained delivery of doxorubicin with potential localised application in cancer treatments.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CNN; Doxorubicin; Nanosponges; Nigerose; Sustained release

Mesh:

Substances:

Year:  2018        PMID: 29801818     DOI: 10.1016/j.carbpol.2018.04.027

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  5 in total

1.  Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance.

Authors:  Federica Bessone; Chiara Dianzani; Monica Argenziano; Luigi Cangemi; Rita Spagnolo; Federica Maione; Enrico Giraudo; Roberta Cavalli
Journal:  Cancer Drug Resist       Date:  2021-03-19

2.  Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells.

Authors:  Monica Argenziano; Chiara Lombardi; Benedetta Ferrara; Francesco Trotta; Fabrizio Caldera; Marco Blangetti; Hinanit Koltai; Yoram Kapulnik; Ronit Yarden; Luca Gigliotti; Umberto Dianzani; Chiara Dianzani; Cristina Prandi; Roberta Cavalli
Journal:  Oncotarget       Date:  2018-11-09

3.  Improvement in the Anti-Tumor Efficacy of Doxorubicin Nanosponges in In Vitro and in Mice Bearing Breast Tumor Models.

Authors:  Monica Argenziano; Casimiro Luca Gigliotti; Nausicaa Clemente; Elena Boggio; Benedetta Ferrara; Francesco Trotta; Stefania Pizzimenti; Giuseppina Barrera; Renzo Boldorini; Federica Bessone; Umberto Dianzani; Roberta Cavalli; Chiara Dianzani
Journal:  Cancers (Basel)       Date:  2020-01-09       Impact factor: 6.639

4.  Cyclic Nigerosyl-Nigerose as Oxygen Nanocarrier to Protect Cellular Models from Hypoxia/Reoxygenation Injury: Implications from an In Vitro Model.

Authors:  Claudia Penna; Saveria Femminò; Fabrizio Caldera; Alberto Rubin Pedrazzo; Claudio Cecone; Edoardo Alfì; Stefano Comità; Takanobu Higashiyama; Francesco Trotta; Pasquale Pagliaro; Roberta Cavalli
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

Review 5.  Nanosponges for Drug Delivery and Cancer Therapy: Recent Advances.

Authors:  Siavash Iravani; Rajender S Varma
Journal:  Nanomaterials (Basel)       Date:  2022-07-16       Impact factor: 5.719

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.